Philips and icometrix advance precision diagnosis in neurology with innovative AI-based imaging solutions at #RSNA24
25 Novembre 2024 - 3:00PM
UK Regulatory
Philips and icometrix advance precision diagnosis in neurology with
innovative AI-based imaging solutions at #RSNA24
November 25, 2024
icometrix’ FDA-cleared quantitative brain solution for
neurological conditions including Alzheimer’s and multiple
sclerosis is seamlessly integrated into Philips next generation
BlueSeal MR scanners, and will be deployed in its comprehensive
informatics platform
Amsterdam, the Netherlands and Leuven, Belgium –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health
technology, and computer-aided diagnostics company icometrix
(Leuven, Belgium) have teamed up to deploy an AI-driven, end-to-end
solution for acquiring, reading, and reporting the results of MRI
brain scans to optimize diagnosis and treatment monitoring of
neurological conditions including Alzheimer’s and multiple
sclerosis (MS). Unveiled at RSNA 2024, icometrix’s unique
AI-powered quantitative reporting software is seamlessly integrated
into Philips’ latest BlueSeal MR scanners through Philips’ new
Smart Reading capability [1], providing consistent and more
accurate diagnosis. The software will also be deployed on Philips’
healthcare informatics platform – including Philips cloud-based AI
Manager.
The introduction of new drugs that slow the progression of
Alzheimer’s emphasizes the critical role of MRI in patient
management. By leveraging advanced MRI techniques, neurologists can
identify the most suitable candidates for these therapies, ensuring
timely and personalized treatment. AI's ability to extract
quantitative measurements from brain scans enhances the diagnostic
process, enabling quicker decision making and improved monitoring
of disease progression. This integration of technology increases
efficiency for healthcare providers and leads to more tailored
treatment.
“Philips is at the forefront of applying AI to help save time and
improve diagnostic accuracy so clinicians can deliver better care
to more patients,” said Shez Partovi, Chief Innovation &
Strategy Officer at Philips. “As these innovations continue to
evolve, they hold great promise for transforming the landscape of
neurological care, offering hope for better management of chronic
conditions like Alzheimer’s and MS. Our partnership with icometrix
is an important step forward in the use of AI to help mitigate
staff shortages, lower the cost of care, increase diagnostic
confidence, and facilitate care orchestration of personalized plans
for the growing number of people who are diagnosed with Alzheimer's
disease."
“Our icobrain imaging AI measures are rapidly becoming the standard
of care for diagnosis and monitoring of neurological conditions,”
said Wim Van Hecke, CEO of icometrix. “MRI quantification is
crucial to unlock precision medicine, especially in the Alzheimer’s
disease care pathway, which is why our partnership with Philips is
so well timed. We have developed the leading AI solutions for brain
MRI monitoring, received CPT III code reimbursement in the US, and
we will be able to support radiologists, neurologists, and people
with neurological conditions at scale through this
collaboration.”
Managing the growing volume of Alzheimer’s imaging
results
Alzheimer’s is the most common form of dementia, accounting for 60%
to 70% of the 55 million dementia cases worldwide [2], with more
than 150 million people likely to be living with dementia,
predominantly Alzheimer’s, by 2050 [3]. With the introduction of
monoclonal antibody drugs that break down the amyloid protein
deposits in the brain that are believed to be the cause of
Alzheimer’s, MRI is now crucial as a part of the diagnostics
process as well as to assess treatment effectiveness and help avoid
adverse side effects. The latest guidelines for using these drugs
involve a minimum of four separate MRI scans during the first year
of treatment. High caseloads and the global shortage of
neuroradiologists – coupled with the time-consuming nature of
manual image reading and difficulty in extracting consistent
quantitative measurements – is already putting a severe burden on
radiology departments.
In addition to icometrix’s icobrain dm software for differential
dementia diagnosis, the solution also includes the company’s
icobrain ARIA software [4]. The only FDA-cleared solution that is
classified as computer-aided detection and diagnosis, Icobrain ARIA
can detect and grade the severity of amyloid-related imaging
abnormalities. Icobrain ARIA quantifies, in a fully automated way,
the extent of a potentially fatal side effect of anti-amyloid drugs
known as amyloid-related imaging abnormalities (ARIA) – typically
fluid buildup in the brain or blood leakage into brain tissue.
Monitoring ARIA over the course of therapy allows neurologists to
adjust a patient’s therapy to minimize these side effects.
Philips’ latest BlueSeal MR scanners are delivered with
standardized AI-based SmartExam planning and AI-accelerated
SmartSpeed protocols to image ARIA quickly and easily. Philips
unique Smart Reading software [4] also allows end-to-end seamless
integration of imaging protocols with the icometrix icobrain ARIA
software to deliver fast, fully automated, quantitative outcomes
for Alzheimer’s patients. Integrated into Philips’ healthcare
informatics platform, these breakthrough AI-driven diagnostic and
therapy monitoring capabilities fit seamlessly into radiology MR
workflows and hospital PACS.
Speeding the differential diagnosis of multiple
sclerosis
To ensure more confident diagnosis of MS, new clinical guidelines
have been introduced that include a special MR imaging protocol and
FLAIR* generation in Philips Advanced Visualization Workspace to
simultaneously create high-quality images of white matter lesions
and veins. Philips is currently the only commercial supplier of MR
scanners that can perform FLAIR* imaging. icometrix icobrain ms,
also seamlessly integrates on the Philips MR scanner and Philips AI
Manager. It counts the number of white-matter lesions forming
around veins – a characteristic highly specific to MS and it also
allows for longitudinal and quantitative comparison of follow-up
MRI exams, which are essential for treatment decision-making.
Philips’ latest neuroimaging solutions and icometrix’s software
solutions for Alzheimer’s and MS will be available on the Philips
BlueSeal 1.5T MR scanners and Philips’ 3.0T MR portfolio. The
solutions will be demonstrated in the Philips booth (6730) and the
icometrix booth (4903) at the Radiological Society of North America
Annual Meeting (RSNA 2024, December 1-4, Chicago, USA). For more
information, visit Philips at RSNA 2024.
[1] BlueSeal XE/SE and Smart Reading is not yet CE marked, not
cleared in all countries, and not yet available for delivery in any
country. Please consult your Philips contact person for
further information.
[2] World Health Organization (WHO), Dementia Key Facts
https://www.who.int/news-room/fact-sheets/detail/dementia
[3] Nichols, Emma et al. Estimation of the global prevalence of
dementia in 2019 and forecasted prevalence in 2050: an analysis for
the Global Burden of Disease Study 2019. The Lancet Public Health,
Volume 7, Issue 2, e105 - e125
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00249-8/fulltext
[4] Philips and Icometrix have the intention to make icobrain aria
software available for reselling in the USA through the Philips
catalog, as well as a Smart Reading solution on MR platforms.
Philips AI Manager is not intended for data interpretation or
diagnosis. Availability of 3rd party algorithm may vary per market.
The functionalities and benefits of the solution depend on
customer-specific configuration and use. Please contact your local
Philips representative for market availability.
For further information, please contact:
Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978 221 8919
E-mail: kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being through meaningful innovation. Philips’ patient- and
people-centric innovation leverages advanced technology and deep
clinical and consumer insights to deliver personal health solutions
for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring,
and enterprise informatics, as well as in personal health. Philips
generated 2023 sales of EUR 18.2 billion and employs approximately
69,300 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
- MR technologist reviews icometrix AI report on the Philips
BlueSeal MRI console
- MR technologist reviews neuro images in icometrix AI reporting
tool
Koninklijke Philips NV (BIT:PHIA)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Koninklijke Philips NV (BIT:PHIA)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024